Meanwhile, a nationwide population-based case-control study found a statistically significantly decreased incidence of PD among diabetic individuals with a record of taking DPP-4 inhibitors (which increase GLP-1 levels) as well as a risk estimate below for GLP-1 agonists [93]. This evidence concerns the gene GLP1R and Parkinson disease.